Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health Chief Financial Officer Oluyemi Okupe reported option exercises and a stock sale involving Class A common stock. On January 5, 2026, Okupe exercised stock options for 2,178 shares at $5.01 and 3,808 shares at $11.53 per share, receiving the same number of Class A shares. On the same day, Okupe sold 9,070 shares of Class A common stock at an average price of $33.7875.
The filing states that these option exercises and sales were carried out under a Rule 10b5-1 trading plan adopted on May 21, 2025. After the reported transactions, Okupe directly held 91,617 Class A shares and indirectly held 7,853 additional shares through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported a sale of Class A common stock. On 12/22/2025, the reporting person sold 23,090 shares at an average price of $35.7172, with trades executed in a price range of $35.36–$35.88. The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025, which is designed to systematically execute trades over time.
After this transaction, the reporting person beneficially owns 94,333 shares of Class A common stock directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated 9-1-2021.
HIMS insider Oluyemi Okupe has filed a Rule 144 notice to sell up to 32,160 shares of common stock through Goldman Sachs & Co. LLC. The planned sale has an aggregate market value of $1,127,208, with the shares listed on the NYSE and 219,270,891 shares of this class outstanding. The shares come from equity compensation, including restricted stock units and stock options acquired between February 2022 and December 2025, with some tied to cashless, same-day option exercises.
Over the prior three months, the same seller completed several sales of HIMS common stock, ranging from 11,592 to 85,000 shares per transaction, for gross proceeds between roughly $669,232 and $5,116,923.50. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported selling 13,750 shares of Class A common stock on 12/17/2025 at $36.71 per share. The transaction was reported with transaction code "S" and was effected under a Rule 10b5-1 trading plan adopted on March 4, 2025.
After this sale, Chi beneficially owns 305,161 shares of Hims & Hers Health, Inc. common stock in direct ownership.
Hims & Hers Health, Inc. director and Chief Policy Officer Deborah M Autor reported selling 7,054 shares of Class A common stock on December 17, 2025 at $36.71 per share. The transaction was filed on Form 4 as a sale of non-derivative securities.
After this sale, she beneficially owned 6,175 shares of Class A common stock, held directly. The filing notes that the sale was effected under a Rule 10b5-1 trading plan adopted on August 11, 2025, indicating the trades followed a pre-established plan.
Hims & Hers Health, Inc. director and Chief Medical Officer Patrick Harrison Carroll reported selling 10,021 shares of Class A common stock on 12/17/2025 at $36.71 per share.
After this transaction, Carroll beneficially owns 169,940 shares of Hims & Hers Class A common stock, held directly. The sale was carried out pursuant to a Rule 10b5-1 trading plan adopted on May 19, 2025.
Hims & Hers Health, Inc. officer Irene Becklund reported selling 8,411 shares of Class A common stock on 12/17/2025 at $36.71 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2024. After this transaction, she directly holds 2,126 shares of Hims & Hers Health stock.
A shareholder has filed a notice of proposed sale covering 10,021 Class A shares, to be sold through Fidelity Brokerage Services LLC on the NYSE with an aggregate market value of 367,870.91. The filing lists an approximate sale date of 12/17/2025.
The shares were acquired on 12/15/2025 through restricted stock vesting from the issuer as compensation. The same seller, Patrick H. Carroll, is also disclosed as having sold 10,021 Class A shares on 09/17/2025 for gross proceeds of 506,060.50 during the prior three months.
This notice reports that shareholder Michael Y. Chi plans to sell 13,750 Class A shares of the issuer on or about 12/17/2025 through Fidelity Brokerage Services on the NYSE. The shares have an aggregate market value of $504,762.50, while total Class A shares outstanding are 219,270,891.
The securities to be sold were acquired from the issuer on 12/15/2025 through restricted stock vesting as compensation, with the same date listed for acquisition and payment. The filing also lists several prior Class A share sales by Michael Y. Chi over the past three months, including 13,749 shares sold on 09/17/2025 for gross proceeds of $694,324.50.
HIMS stockholder Irene Becklund has filed a notice to sell 8,411 Class A shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $308,767.81. The notice also lists 219,270,891 Class A shares outstanding.
The shares to be sold were acquired on 12/15/2025 via restricted stock vesting from the issuer as compensation, with payment also dated that day. Over the prior three months, Becklund sold 8,410 Class A shares on 09/17/2025 for gross proceeds of $424,705.00.
FAQ
What is the current stock price of Hims & Hers Health (HIMS)?
What is the market cap of Hims & Hers Health (HIMS)?
